AYTU BIOPHARMA, INC (AYTU)

Every figure this model derived for AYTU, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 34,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 26,715,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 67,326,000 AssetsCurrent 2026-03-31
current liabilities 59,972,000 LiabilitiesCurrent 2026-03-31
equity 35,143,000 StockholdersEquity 2026-03-31
interest expense 2,242,000 InterestExpenseNonoperating 2026-03-31
ocf 1,678,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 56,599,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-03-31
sbc 658,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up AYTU on one particular measure came for.

RatioValue
cash operating margin-18.07
current ratio1.12
current ratio reported1.12
deferred revenue growth-50.0
dilution pct13.4
fcf margin2.9
growth cv1.88
interest cover-6.76
operating margin-26.79
owner earnings margin1.74
revenue growth-14.04
revenue growth per share-24.2
roic-60.39
rule of 40-40.82
sbc pct revenue1.16

What to be careful about

What this model itself distrusts about AYTU's figures. Written by the derivation as it ran, not added afterwards.